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Abstract
Background: Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from
our group suggested that this occurs via Platelet-activating factor receptor (PAF-R)-mediated pathways. In the
present study, we investigated the impact of apoptotic cell inoculation or induction by a chemotherapeutic agent
(dacarbazine, DTIC) on tumour growth, microenvironmental parameters and survival, and the effect of treatment
with a PAF-R antagonist (WEB2170). These studies were performed in murine tumours: Ehrlich Ascitis Tumour (EAT)
and B16F10 melanoma.
Methods: Tumour growth was assessed by direct counting of EAT cells in the ascitis or by measuring the volume
of the solid tumour. Parameters of the tumour microenvironment, such as the frequency of cells expressing cyclo-
oxygenase-2 (COX-2), caspase-3 and galectin-3, and microvascular density, were determined by
immunohistochemistry. Levels of vascular endothelium growth factor (VEGF) and prostaglandin E2 (PGE2) were
determined by ELISA, and levels of nitric oxide (NO) by Griess reaction. PAF-R expression was analysed by
immunohistochemistry and flow cytometry.
Results: Inoculation of apoptotic cells before EAT implantation stimulated tumour growth. This effect was reversed
by in vivo pre-treatment with WEB2170. This treatment also reduced tumour growth and modified the
microenvironment by reducing PGE2, VEGF and NO production. In B16F10 melanoma, WEB2170 alone or in
association with DTIC significantly reduced tumour volume. Survival of the tumour-bearing mice was not affected
by WEB2170 treatment but was significantly improved by the combination of DTIC with WEB2170. Tumour
microenvironment elements were among the targets of the combination therapy since the relative frequency of
COX-2 and galectin-3 positive cells and the microvascular density within the tumour mass were significantly
reduced by treatment with WEB2170 or DTIC alone or in combination. Antibodies to PAF-R stained the cells from
inside the tumour, but not the tumour cells grown in vitro. At the tissue level, a few cells (probably macrophages)
stained positively with antibodies to PAF-R.
Conclusions: We suggest that PAF-R-dependent pathways are activated during experimental tumour growth,
modifying the microenvironment and the phenotype of the tumour macrophages in such a way as to favour
tumour growth. Combination therapy with a PAF-R antagonist and a chemotherapeutic drug may represent a new
and promising strategy for the treatment of some tumours.
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Background
There is evidence that macrophages have the capacity to
change their phenotype in response to changes in the
microenvironment. It has been suggested that M1 and
M2 represent the extremes of a variety of phenotypes
that macrophages can express and that the M2 pheno-
type is associated with suppressor functions [1,2]. It has
been shown that apoptotic cells induce macrophage
polarization towards a suppressive phenotype. Fadok et
al [3] reported that the addition of apoptotic cells to
LPS-stimulated macrophages shifts the type of media-
tors/cytokines produced from a pro-inflammatory
towards a suppressive profile. The recognition of apop-
totic cells by macrophages is achieved through mole-
cules that are expressed in the plasma membrane of
apoptotic cells and bind to a variety of receptors present
on the surface of the macrophages, resulting in the pha-
gocytic removal of altered or dying cells [4]. We have
previously found that the rate of phagocytosis of apopto-
tic cells is higher than that of viable cells and that this
potentiation is abolished if macrophages are treated
with an antagonist of the PAF-R. Moreover, the interac-
tion of macrophages with apoptotic cells induces the
expression of COX-2, the inducible enzyme that is
responsible for the synthesis of prostaglandins and is
also inhibited by treatment with the PAF-R antagonist
[5]. One of the products of this enzyme is PGE2, which
exerts suppressive actions through interaction with EP2
or EP4 receptors in the macrophage [6]. PAF-R is a G-
protein-coupled receptor that is present in the plasmatic
and nuclear membrane and also in the cytoplasm of var-
ious cell types including macrophages. Depending on its
localization, the receptor is linked to different sub-units
of G-protein, Gaq or Gai/o and thus activates distinct
intracellular signaling cascades [7].
The findings that apoptotic cells share common
ligands with PAF, that apoptotic cells dampen macro-
phage activation and that PAF-R is somehow involved
in these effects could be particularly relevant in the case
of tumour growth. As the number of tumour cells
increases during tumour development, many of these
cells die by apoptosis or necrosis due to the reduction
in oxygen and nutrient supply. Induction of apoptosis is
also the mechanism of action of anti-tumour che-
motherapy. Correa et al [8] clearly demonstrated that
apoptotic cells injected together with a sub-tumouri-
genic dose of B16F10 melanoma cells promote tumour
growth. This could be attributed to the postulated sup-
pressor effect of apoptotic cells on macrophages but
whether it is dependent on PAF-R remains to be deter-
mined. Antagonists of PAF-R have been tested in some
tumours: in human breast cancer they inhibited cell pro-
liferation in vitro and reduced the formation of new
vessels in tumours induced by implantation of these
cells [9]; in B16F10 murine melanoma they decreased
lung metastasis [10]; in EAT they reduced tumour
growth [11].
Based on the data discussed above we postulated that
the interaction of macrophages with apoptotic cells in
the tumour microenvironment, through PAF-R-depen-
dent mechanisms, would drive macrophage polarization
towards a suppressive phenotype favoring tumour
growth. In the present study we investigated this
hypothesis in two murine tumours: EAT and melanoma
B16F10. Apoptotic cells were either inoculated into the
tumour or induced by dacarbazine (DTIC), an agent
that is widely used in human melanoma therapy. The
role of the PAF-R was evaluated using the antagonist
WEB2170. Tumour growth was evaluated by counting
the cells in the ascitis or measuring tumour volume.
The tumour microenvironment elements that were ana-
lysed were the levels of PGE2, VEGF and NO in the
ascitis and, in the melanoma, the number of cells
expressing COX-2, the number of intra-tumoural blood
vessels and tumour infiltration by activated macro-
phages/dendritic cells expressing galectin-3, which is
associated with the suppressive M2 phenotype. PAF-R
expression was evaluated in cells from inside the tumour
and in melanoma cells taken from cultures.
Methods
Animals
Seven- to 10-week-old male BALB/C and 7- to 8-week-
old female C57BL/6 mice from our own animal facilities
were used. All animal procedures were in accordance
with the ethical principles adopted by the Brazilian Col-
lege of Animal Experimentation and approved by the
Ethical Committee for Animal Research of the Institute
of Biomedical Sciences, University of São Paulo.
Tumours
The murine melanoma cell line B16F10 was a kind gift
from I. Fidler (M.D. Anderson, Texas, USA) and was
cultured in RPMI 1640 medium (Cultilab, Campinas,
Brazil), pH 7.4 supplemented with 10% fetal bovine
serum (FBS, Cultilab, Campinas, Brazil), in the absence
of antibiotics, at 37°C and 5% CO2. Ehrlich ascitis
tumour (EAT) cells were grown as described elsewhere
[12].
Evaluation of tumour growth
Ehrlich ascitis tumour (103-105 cells) was injected intra-
peritoneally (i.p.) in BALB/c mice. At different times after
tumour implantation, aliquots of the ascitis fluid were
recovered using a 21-gauge needle to measure cell number
and mediator/cytokine levels. B16F10 melanoma cells
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(5 × 105) were injected subcutaneously (s.c.) in C57BL/6
mice and tumour growth was determined via measure-
ment of the diameter of the solid tumour mass, from
which the volume was estimated using the formula for a
spheroid: V = 0.52 × (largest axis) × (smallest axis)2.
Treatments
The PAF-R antagonist WEB2170 (5 mg/Kg; Boehringer
Ingelheim, Germany) was injected i.p. 30 minutes before
tumour implantation and injections were repeated every
24 h until the end of the experiment. In order to evalu-
ate the possible benefit of the combined therapy with
WEB2170, treatment with the chemotherapeutic drug
DTIC was chosen at a suboptimal regimen based on
previously published studies [13,14]. In our study 40 μg
DTIC (Sigma Chem. Co.) was given i.p. to each mouse
every 3 days after tumour implantation. To determine
the impact of these treatments on the survival of
B16F10 melanoma-bearing mice, the treatment proto-
cols were extended to 35 days. The Kaplan-Meier
method and the log-rank test were used to estimate and
compare the different groups.
Quantification of VEGF, PGE2 and nitrite in
the ascitis fluid
At day 10 of EAT growth, BALB/C mice were sacrificed
and the ascitis fluid was recovered. The suspension was
centrifuged (180 × g for 10 min) and VEGF levels were
determined in the supernatant by ELISA using goat
polyclonal antiserum against mouse VEGF (Santa Cruz
Biotechnology, Inc.). PGE2 levels were also determined
by ELISA using a commercially available kit (Cayman
Chem. Co.). NO levels were determined according to
the method described by Bartholomew (1984) [15].
Briefly, aliquots of 150 μL of the ascitis fluid were trea-
ted with 15 μL of 10% ZnSO4 solution for 10 minutes at
4°C. Three μL of 2.5 N NaOH were added and the asci-
tis fluid was incubated at 4°C for 10 minutes. The NO3
-
content was converted to NO2
- through addition of 15
μL of 0.5 M NaH2PO4, 15 μL of 2.4 M ammonium for-
miate and 10 μL of a suspension of E. coli to the ascitis
fluid. The bacterium E. coli expresses nitrate reductase,
which catalyses the conversion of nitrate to nitrite. Sam-
ples were further incubated at 37°C for 2 h, centrifuged
(18000 × g for 5 min at 20°C), and 100 μL of Griess
Reagent (0.1% N-naphthyl-ethyl-indiamine, 1% sulphani-
lamide, 2.5% orthophosphoric acid - Sigma Co.) were
added to the same volume of the supernatant. NO levels
were quantified in a spectrophotometer at 540 nm.
Characterization of apoptotic and necrotic cells in the
ascitis fluid
BALB/C mice were inoculated i.p. with 1 × 103 EAT
cells and sacrificed after 7 or 10 days. The peritoneal
cavity was injected with 3 mL of PBS to recover the
ascitis. The fluid was centrifuged (180 × g for 10 min)
and the cell pellet resuspended in 1 ml of RPMI 1640
with 10% fetal calf serum. Trypan Blue dye (0.2%) was
added to aliquots of cellular suspensions and the per-
centage of cells that had taken up the dye (necrotic
cells) was determined microscopically. The percentage
of apoptotic cells was determined by flow cytometry
(FACScalibur, Becton Dickinson, San Jose, CA) after
incubation of 3 to 5 × 105 cells with propidium iodide
(20 μg/mL in 0.1% sodium citrate and 0.1% Triton X-
100) at 4°C for 2 h in the dark.
Induction of apoptosis in murine thymocytes
Murine thymocytes were obtained through surgical extrac-
tion of the thymus from BALB/C mice. After thymus
dissociation, the thymocyte suspension was centrifuged
(400 × g, 4°C, 7 min), the pellet was resuspended in RPMI
medium and cell viability was determined using Trypan
Blue vital dye. After this, thymocytes were g-irradiated
(450 rad) and incubated at 37°C for 18 hours. Apoptotic
cells were detected by annexin V staining and the percen-
tage of apoptotic cells was measured by flow cytometry
(FACS, Becton-Dickinson, CA), as described elsewhere [5].
To evaluate the effect of apoptotic thymocytes on EAT
growth, BALB/C mice were inoculated with 6 × 106 viable
or apoptotic thymocytes into the peritoneal cavity 2 h
before the inoculation of 1 × 105 EAT cells. Animals were
sacrificed after 5 days and aliquots of the ascitis fluid were
recovered to estimate EAT growth via direct cell counting
in a Neubauer chamber under a light microscope.
Histological, immunohistochemistry and morphometric
analysis of melanoma specimens
Tumours derived from B16F10 melanoma cells were
excised and processed for immunohistochemistry to
detect the expression of galectin-3 (1:32, ATCC), PAF-R
(1:80; Cayman), COX-2 (1:100; Santa Cruz) and acti-
vated caspase-3 (1:600; Cell Signaling). Reactions were
performed as described elsewhere [16,17]. Images of dif-
ferent areas of each tumour specimen were acquired
with a digital camera DXM 1200F (Nikon) and quantita-
tive analysis was performed using Eclipse Net software
(Nikon). For percent area measurements, grids were
projected on tissue sections and the number of grid
intersections that overlaid a cell with a specific type
(identified by immunohistochemistry reaction) or func-
tional blood vessels (identified by routine H&E staining
and by the identification of blood cells) was counted.
Data were expressed as percent area occupied by vessels
or cells expressing a given marker (COX-2-expressing
cells, galectin-3-expressing cells, and activated caspase-
3-expressing cells). The total number of cells positively
stained by each marker was determined by counting
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multiple grids randomly placed on tissue sections at
medium power field magnification (40×). Spleens were
also processed for immunohistochemistry to detect cells
expressing galectin-3 in the white pulp.
Preparation of cell suspensions from tumours
Tumours were excised and kept in RPMI 1640 at 4°C
for immediate processing. All collected tumours were
washed in ice-cold PBS, finely minced and transferred
to 60 mm-diameter Petri dishes containing 1 mL MTH
(HBSS, 0.5 U/mL DNAse in 15 mM HEPES) supple-
mented with 0.15 Wunsch units/mL of Liberase Blend-
zyme 3 (Roche). Fragments were incubated for 30
minutes at 37°C under constant agitation (80 rpm) for
mechanical dissociation. Cell suspensions were then fil-
tered using nylon membranes (41 μm pores). The fil-
trate was centrifuged at 4°C (1200 rpm for 5 min),
washed in cold PBS and resuspended in 3 mL of red
blood cell lysis solution (Amersham Biotech). After 3
min, another 3 mL of RPMI 1640 was added to the sus-
pension, which was then centrifuged as above and
washed in PBS. Cell number was then determined by
direct counting using a Neubauer chamber.
Flow cytometry
For flow cytometry experiments, a million cells were sepa-
rated for each reaction tube or well. Cells were washed
with PBS-BSA (PBS containing 0.5% BSA) and then incu-
bated with an Fc blocker antibody for 15 min at 4°C. Cells
were then centrifuged (1200 rpm for 5 min at 4°C),
washed with PBS-BSA and incubated with 0.3 μg/mL of a
rabbit polyclonal anti-PAF-R antibody (Cayman Chemical,
USA) for 60 min on ice. After washing, cells were incu-
bated with a FITC-labeled anti-rabbit IgG for 30 min on
ice in the dark. After washing, the cells were then sus-
pended in 2% formaldehyde in PBS and kept in the dark
until acquisition and analysis in a flow cytometer (FACS-
calibur, Becton Dickinson, San Jose, CA, USA). Histogram
analysis was done using the CellQuest software. The con-
trol samples were incubated with the Fc blocker and with
the FITC-labeled secondary antibody.
Statistical analysis
Data were analysed using ANOVA followed by Tukey or
Bonferroni post-hoc tests. Survival was analysed by the
Kaplan-Meier method and survival curves were com-
pared using the log-rank test. Differences were consid-
ered significant when p < 0.05.
Results
Apoptotic cells favour EAT growth through
PAF-R-dependent pathways
Fig. 1A shows the kinetics of EAT growth following
implantation of 1 × 103 tumour cells into the peritoneal
cavity of BALB/c mice. The number of cells present in
the ascitis fluid was counted on days 1, 7 and 10 after
implantation. It can be seen that the number of cells in
the peritoneal cavity increased progressively. Whereas at
day 7, around 92% of the cells were EAT cells, at day 10
virtually all cells identified in the differential counts
were EAT cells. Treatment with the PAF-receptor
antagonist WEB2170 (5 mg/kg) significantly reduced the
number of tumour cells, markedly after 10 days of treat-
ment (Fig. 1 A). The percentage of apoptotic cells in the
ascitis fluid after 7 and 10 days of tumour growth was
less than 2%. The percentage of necrotic cells was also
less than 2%, although this percentage was lower at 10
days compared to 7 days of tumour growth in the
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Figure 1 Phagocytosis of apoptotic cells through PAF-R affects
EAT growth. EAT cells (1 × 103 cells) were inoculated into the
peritoneal cavity of BALB/c mice. Ascitis fluid was collected at
different times after tumour implantation and the cell number was
determined using a Neubauer chamber. (A) Animals were injected i.
p. with phosphate buffered saline (PBS) or WEB2170 (5 mg/Kg) 30
min before EAT cells and daily for 6 days (n = 3-4). (B) Live or
apoptotic thymocytes (6 × 106) were inoculated i.p. 2 h before
implantation of EAT. WEB2170 (5 mg/Kg) was given i.p. 30 min
before the thymocytes. Cell number was determined 5 days after
tumour implantation (n = 17-21). Data represent the mean ± SEM
of the number of EAT cells. Statistical analyses were performed
using ANOVA and SNK (Student Neumans-Keuls test) and
differences were considered significant at p < 0.05. (*) p < 0.05
compared to control groups.
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control PBS group (Table 1). Whereas in the non-trea-
ted group, the percentage of necrotic cells tended to
decrease with time, in the treated group, the percentage
of necrotic cells remained constant. On the other hand,
considering the total number of cells in the peritoneal
cavity at these time-points of tumour growth, the abso-
lute quantities of both apoptotic and necrotic cells were
higher in the animals within the non-treated group.
In another set of experiments, Balb/c mice received an
i.p. injection of 6 × 106 live or apoptotic thymocytes 2 h
before implantation of EAT into the peritoneal cavity.
Animals were sacrificed at day 5 of tumour growth and
the total number of cells present in the ascitis fluid was
determined (at that time more than 90% of the perito-
neal cells were tumour cells). The results showed that
previous inoculation of apoptotic but not live thymo-
cytes increased EAT growth, as total cell counts were
about 2-fold higher (p < 0.05) in this group than in the
control group (Fig. 1B). Mice were also either treated
with WEB2170 or PBS (as a control) 30 min before
inoculation of the thymocytes to investigate the possible
involvement of PAF-R in the potentiating effect of apop-
totic cells. We observed that treatment with a single
dose of WEB2170 reverted the stimulatory effect of
apoptotic cells on EAT growth, whereas no effect was
observed on tumour growth in mice inoculated with
viable cells (Fig. 1B).
Activation of PAF-R-dependent pathways led to increased
secretion of PGE2, VEGF and NO in the ascitis fluid
High levels of PGE2, which has a suppressor effect on
some macrophage functions [11], and of VEGF, which
plays an important role in tumour growth due to its
pro-angiogenic activity [18], were apparent in the mice
peritoneal cavity during EAT growth. In addition, activa-
tion of PAF-R was shown to induce PGE2, VEGF and
NO [19]. We then investigated the effect of a PAF-R
antagonist on these molecules in the ascitis fluid 7 days
after tumour implantation (1 × 105 EAT cells). Mice
were treated with WEB2170, 30 min before tumour
implantation and daily up to the 6th day. The levels of
PGE2 (Fig. 2A), VEGF (Fig. 2B) and NO detected as the
NO2
- concentration (Fig. 2C) in the ascitis fluid were
increased in EAT-bearing animals at this time. Treat-
ment with WEB2170 significantly decreased the levels of
all three mediators.
Combined therapy with WEB2170 and DTIC in
EAT growth
The pro-tumoural effect observed with the addition of
apoptotic thymocytes before EAT implantation
prompted us to evaluate a more realistic scenario,
namely the impact of blocking PAF-R-dependent path-
ways during the course of chemotherapy. DTIC (40 μg
injected i.p. every 3 days after tumour implantation) was
chosen as the chemotherapeutic drug, based on its capa-
city to induce apoptosis in a wide variety of tumour cells
in in vivo models [13]. It can be seen in Table 2 that the
number of tumour cells 10 days after implantation in
BALB/c mice inoculated i.p. with 1 × 105 EAT cells was
significantly reduced by treatment with DTIC (77%) or
WEB2170 (76%). The combined treatment with both
DTIC and WEB2170 was around three times more
effective than either treatment alone.
Combined therapy with both WEB2170 and DTIC
prolonged the survival of melanoma-bearing mice
The effect of treatments with WEB2170 and DTIC was
then evaluated in a solid tumour, the B16F10 murine
melanoma model. Tumour cells (5 × 105) were injected
s.c. in C57Bl/6 mice. Fig. 3A shows the kinetics of mela-
noma growth after tumour cell implantation. A marked
delay in tumour growth was observed in animals receiv-
ing WEB2170, either alone or combined with DTIC,
which was significant 10-12 days after tumour implanta-
tion (Fig. 3A). At day 12, animals were sacrificed and
the tumours were analysed by immunohistochemistry.
Regardless of the initial delay in tumour growth, survival
of melanoma-bearing animals receiving WEB2170 alone
was not significantly different from the survival of either
melanoma-bearing animals in the control group (PBS
group, Fig. 3B), or animals receiving DTIC alone. How-
ever, the association of both DTIC and WEB2170
prolonged the survival of melanoma-bearing mice
significantly (Fig. 3B).
Tumour microenvironment elements are targets for
the combined therapy with DTIC and WEB2170 in
murine melanoma
Tumour cell and tumour microenvironmental para-
meters, such as the relative frequency of apoptotic cells
(caspase-3 positive) within the tumours (Fig. 4A), the
relative frequency of COX-2 positive cells (Fig. 4B),
Table 1 Effect of WEB2170 treatment on the percentage
of apoptotic and necrotic cells during EAT growth.
Apoptotic cells % of total cells
PBS WEB2170
Day 7 Day 10 Day7 Day 10
0.98 ± 0.98 1.38 ± 0.62 0.62 ± 0.26 1.72 ± 0.45
Necrotic cells 1.50 ± 0.35 0.30 ± 0.11(#) 0.60 ± 0.31(*) 0.70 ± 0.30
1 × 103 EAT cells were i.p. injected in BALB/C mice and the ascitis fluid was
collected after 7 and 10 days to determine the percentage of apoptotic and
necrotic cells. WEB2170 (5 mg/Kg; i.p.) was given 30 min before inoculation of
EAT cells.
(*) p < 0.05 comparing WEB2170-treated with PBS group
(#) p < 0.05 comparing day 10 with day 7 within PBS or WEB2170 group
n = 3-9 animals/group
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microvascular density (Fig. 4C), and the relative fre-
quency of galectin-3 positive cells, used as a marker for
alternatively activated M2 macrophages or dendritic
cells (Fig. 4D), were analysed via immunohistochemistry
of tumours obtained from the four groups studied,
namely control (PBS group), DTIC or WEB2170 (DTIC
or WEB groups), and combined DTIC and WEB2170
(W + D group).
Apoptotic cells were quantified using antibodies react-
ing with activated caspase-3. The frequency of caspase-3
positive cells within the tumour was slightly but signifi-
cantly lower in the group receiving both DTIC and
WEB2170. No significant changes were found in the
other groups (Fig. 4A). Although statistically significant,
this slight decrease in the frequency of apoptotic cells
within the tumours of animals treated with both DTIC
and WEB2170 may not be the cause of the prolonged
survival of this group of animals. Regardless, the result
suggests that prolonged survival was not due to a direct
increase in the cytotoxic effect of DTIC on tumour
cells. If this were the case, we would expect to observe
an increase in apoptotic cells within the tumour. We
then investigated whether the treatments described
above interfered with selected aspects of the tumour
microenvironment.
Treatment with WEB2170 alone led to a significant
decrease in the frequency of COX-2 positive cells within
the microenvironment of melanoma tumours (Fig. 4B).
Combination of DTIC with WEB2170 counteracted the
reduction in COX-2 positive cells, whose proportion
within the tumours was no longer significantly different
from that in either the control or DTIC alone groups (Fig.
4B). Microvascular density was significantly lower in both
groups receiving WEB2170 (either alone or combined
with DTIC), as shown in Fig. 4C. A decrease in microvas-
cular density occurred in parallel with a significant
decrease in the relative frequency of galectin-3 positive
cells present within the tumour microenvironment, as
shown in Fig. 4D. The relative proportion of galectin-3-
expressing macrophages/dendritic cells in the splenic
white pulp increased significantly upon DTIC treatment
(Fig. 4E). Upon combination of both DTIC and WEB2170,
the proportion of galectin-3-expressing cells in the white
pulp was slightly lower than in the WEB2170 and DTIC
treatments alone (PBS and WEB, Fig. 4E). Taken together,
these results suggest that cellular elements of the tumour
microenvironment are the key targets of the treatment
with WEB2170. As shown in Fig. 5, antibodies to PAF-R
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Figure 2 PAF receptor antagonist reduces PGE2, VEGF and NO
levels in the ascitis fluid. EAT cells (1 × 105) were inoculated i.p.
into BALB/c mice and the levels of PGE2, VEGF and nitric oxide (NO)
were measured in the ascitis fluid 7 days later. One group of mice
was treated with WEB2170 (5 mg/Kg), 30 min before tumour
implantation and daily up to the 6th day. Data represent the mean
± SEM (n = 3-7). Statistical analyses were performed using ANOVA
and SNK (Student Neumans-Keuls test) and differences were
considered significant at p < 0.05. (*) p < 0.05 compared to non-
treated group. In each graph, the first column represents the
baseline levels, determined in the washings of the peritoneal cavity
of mice without tumours, the second column represents the levels
in tumour-bearing mice without treatment (PBS-control group), and
the third column represents tumour-bearing mice treated with
WEB2170.
Table 2 Effect of WEB2170, DTIC and combined
treatment on EAT growth
Treatment ×106 cells
Non treated 66.01 ± 16.07
DTIC 14.99 ± 6.16(*)
WEB2170 15.38 ± 4.26(*)
W + D 4.55 ± 2.16(*)
1 × 105 EAT cells were i.p. injected in BALB/c mice and after 10 days, the
ascitis fluid was collected to determine tumour growth. WEB2170 (5 mg/Kg; i.
p.) was given 30 min before inoculation of EAT cells and DTIC (40 μg/animal;
i.p.) was given every 3 days after tumour implantation.
(*) p < 0.05 compared with non treated group
n = 5-9 animals/group
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stained the cells derived from tumours, but did not stain
the B16F10 melanoma cells grown in vitro (Fig. 5A). At
the tissue level, a few cells stained positively with antibo-
dies to PAF-R (Fig. 5B), suggesting that infiltrating mono-
nuclear cells (probably macrophages or dendritic cells)
were the major cellular targets for WEB2170 in the model
we studied herein.
Discussion
PAF-R is a G-protein-coupled receptor that can be
found in cellular and nuclear membranes. These
receptors are coupled to distinct G proteins and can
thus trigger distinct signaling pathways. Upon binding
of PAF or PAF-like molecules to the PAF-R present in
the cell membrane of macrophages, several mediators/
cytokines [20] and pro-angiogenic factors such as VEGF
are released, angiogenesis being considered one of the
important actions of PAF [21,22]. Prostaglandins are
also produced by macrophages upon PAF-R engagement
and PGE2 exerts anti-inflammatory actions through its
interaction with the prostaglandin EP2 and EP4 recep-
tors, which leads to increased intracellular levels of
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Figure 3 PAF-receptor antagonist, WEB2170, inhibits melanoma growth and in combination with chemotherapy improves the survival
of melanoma-bearing mice. (A) B16F10 melanoma cells (5 × 105) were injected s.c. into C57BL/6 mice and tumours were measured daily with
a caliper. Tumour volume was calculated by the formula: maximum diameter × (minimum diameter)2 × 0.52. WEB2170 (5 mg/Kg) was given i.p.
30 minutes before the tumour followed by daily injections for 12 days. DTIC (40 μg/animal) was injected i.p. every 3 days after tumour
implantation. Data represent the mean ± SEM of tumour volume (n = 5). (B) The Kaplan-Mayer survival curve. For the survival experiments,
WEB2170-treatment was given once a day and DTIC every 3 days for 35 days or until the animals died (n = 8-9). Statistical analyses were
performed using the log rank test and differences were considered significant at p < 0.05. (*) p < 0.05 compared to PBS group.
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Figure 4 Combined therapy with PAF-receptor antagonist and dacarbazine targets both tumour and microenvironmental elements.
B16F10 melanoma cells (5 × 105) were injected s.c. into C57BL/6 mice and after 12 days the tumours were excised and processed for
immunohistochemistry analysis with antibodies to caspase-3 (A), COX-2 (B), CD34 (C) or galectin-3 (D). Alternatively, spleens of animals of the
very same groups and of naïve mice were analysed for the presence of galectin-3-expressing cells in the white pulp (E). WEB2170 (5 mg/Kg) was
given 30 min before the tumour followed by daily injections for 12 days. DTIC (40 μg/animal) was injected i.p. every 3 days after tumour
implantation. Morphometric analyses were performed using Eclipse Net software (Nikon). Grids were projected onto tissue sections and the
number of grid intersections that overlaid an immunoreactive cell was counted. Results are expressed as the % of area occupied by the cells
expressing a given marker (frequency). Data represent the mean ± SEM of positive cells (n = 10). Statistical analyses were performed using
ANOVA and SNK (Student Neumans-Keuls test) and differences were considered significant at p < 0.05. (*) p < 0.05 comparing treated with non-
treated (PBS) groups.
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cAMP and inhibition of macrophage activation [6].
These aspects are particularly important when studying
tumours, since macrophages that are present in the
tumour microenvironment are key actors in both angio-
genesis and tumour immune escape. However, the role
of PAF/PAF-like molecules and PAF-R as modulators of
the tumour microenvironment is still incompletely
understood.
We have previously shown that PAF-R-dependent
mechanisms are involved in the interaction of macro-
phages with apoptotic cells [5]. In the present study we
examined the effect of apoptotic cells and PAF-R on
tumour growth. This was done using two murine
tumours: the Ehrlich ascitis tumour and the melanoma
B16F10. Apoptotic cells were either inoculated into the
tumour or induced by the chemotherapeutic drug
Figure 5 PAF-R is expressed within the tumour microenvironment. (A) The presence of PAF-R was evaluated by FACS analysis in cell
suspensions from B16F10-derived tumours (histograms on the left). Examples from either mock (PBS) or dacarbazine (DTIC)-treated animals are
illustrated. The histograms shown represent the negative control (ctl) and reactivity with the antibody to PAF-R. Cells from within the tumours
stained positively with the antibody to PAF-R. The histogram on the right represents the absence of reactivity for the antibody to PAF-R in
B16F10 cells grown in vitro. (B) Immunohistochemistry of B16F10-derived tumours using the same antibody to PAF-R, showing specific reactivity
to a few cells infiltrating the tumours, consistent with the notion that only a subpopulation of cells within the tumour microenvironment express
the PAF-R (arrow indicates a stained cell).
de Oliveira et al. BMC Cancer 2010, 10:200
http://www.biomedcentral.com/1471-2407/10/200
Page 9 of 12
DTIC. The role of the PAF-R was evaluated using the
antagonist WEB2170. We found that previous inocula-
tion of apoptotic cells into the peritoneal cavity
increased EAT growth. The potentiation of tumour
growth by apoptotic cells was abolished when animals
were treated with WEB2170 before apoptotic cell inocu-
lation. WEB2170 treatment modified the tumour micro-
environment since it decreased the levels of VEGF,
PGE2 and NO in the ascitis fluid. In the B16F10 mela-
noma model, treatment with DTIC reduced tumour
growth and increased the survival rate only when asso-
ciated with WEB2170, thus indicating that PAF-R
engagement by PAF/PAF-like molecules that are present
on apoptotic cells or free in the microenvironment
modulate the response of the tumour to chemotherapy.
Treatment with WEB2170 alone or associated with
DTIC also modified the tumour microenvironment by
reducing the number of intra-tumoural blood vessels
and tumour infiltration by macrophages/dendritic cells
expressing galectin-3, a molecule that is associated with
the suppressive M2 phenotype.
These data suggest that PAF-R-dependent mechan-
isms are able to modify tumour microenvironment ele-
ments, including tumour macrophages, during EAT
growth. In previous studies in our laboratory, we
observed that whereas macrophages taken from the nor-
mal peritoneal cavities of mice were able to produce
hydrogen peroxide and spread across a glass surface,
those taken from mice with EAT retained the round
morphology characteristic of non-activated macrophages
and were unable to produce hydrogen peroxide [12].
However, macrophage spreading and H2O2 production
in tumour-bearing mice was restored after treatment in
vivo with antagonists of the PAF-R (BN52021 or
SRI63441), and this was accompanied by a significant
reduction in EAT growth [11]. This was the first indica-
tion that engagement of PAF-R can modify the macro-
phage phenotype and modulate tumour growth. In the
present study we confirmed the EAT growth inhibition
by a PAF-R antagonist distinct from that used in pre-
vious studies, i.e. WEB2170, which belongs to a group
of triazolodiazepinic compounds and has been shown to
antagonize the effects of PAF in several cells and tissues
[23]. The same dose of WEB2170 that was effective in
the latter studies to antagonize the effects of PAF in
vivo was used in our experiments. Participation of PAF-
R was also observed in a solid tumour where WEB2170
significantly reduced the growth of melanoma B16F10.
As tumours grow, a number of tumour and host cells
die. The process of cell death is accompanied by oxida-
tion of membrane phospholipids. We have previously
shown that apoptotic cells express PAF-like molecules,
which share a common or related receptor with oxLDL
and PAF in macrophages [5]. We thus evaluated the
impact of apoptotic cells on tumour growth and the
contribution of WEB2170. It was found that inoculation
of apoptotic cells with the EAT cells increased tumour
growth and that this effect was abrogated by treatment
of mice with WEB2170 prior to the injection of apopto-
tic cells. In a solid tumour, melanoma B16F10, the com-
bination of WEB2170 with the chemotherapeutic agent
DTIC, which induces apoptosis, increased the survival of
melanoma-bearing mice. These data suggest that inter-
action of PAF-like molecules on the surface of apoptotic
cells with PAF-R that are present in the tumour micro-
environment (presumably in tumour macrophages) has
an important modulatory effect during the initial stages
after tumour cell implantation. This may also be the
case for the B16F10 melanoma model, where the survi-
val time was improved only when DTIC treatment was
associated with daily WEB2170 treatment, which began
as early as 30 min before melanoma cell inoculation.
Although treatment of melanoma-bearing mice with
WEB2170 reduced melanoma growth it did not prolong
survival, indicating that the efficacy of treatment was
limited to a narrow time window in the initial phase of
tumour growth. Another possibility that has to be con-
sidered is that increased survival could be related to
inhibition of tumour metastasis [14]. Indeed, Im et al
[10] demonstrated that PAF increases the metastasis of
melanoma B16F10 into the lungs of C57Bl6 mice.
Blocking PAF-R also modified other elements of the
tumour microenvironment such as the increased levels
of PGE2, NO and VEGF produced during EAT growth.
Moreover, in melanoma the PAF-R antagonist reduced
the proportion of COX-2-expressing cells, the microvas-
cular density, and the proportion of activated macro-
phages/dendritic cells expressing galectin-3 within the
tumour microenvironment. These alterations did not
contribute to the control of the melanoma, unless the
animals were given the chemotherapeutic agent DTIC.
Interestingly, as shown in Fig. 4, treatment of animals
with DTIC alone also failed. A common cause of che-
motherapy failure is the phenomenon of tumour cell
repopulation [14,24,25]. It is conceivable that release or
exposure of PAF/PAF-like molecules by dying cells
would affect the phenotype of tumour macrophages and
the tumour microenvironment, as suggested by our
study. Seo and colleagues [26] showed that exogenously
added PAF stimulated B16F10 growth and attenuated
etoposide-induced cell death, via activation of anti-apop-
totic gene expression. This can be interpreted as show-
ing that the engagement of PAF-R by the agonist
produces the same effect as the apoptotic cells in
favouring tumour growth by suppressing tumour macro-
phages. Indeed the frequency of galectin-3, which is a
marker of suppressor macrophages, was lower in the
group treated with the PAF-R antagonist. Correa et al
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showed that inoculation of apoptotic cells along with
sub-tumourigenic inocula of melanoma cells favoured
melanoma growth [8]. This finding strengthens our
hypothesis that the presence of apoptotic cells in the
tumour microenvironment favours tumour growth.
We have shown the expression of PAF-R in homoge-
nates of melanoma but not in melanoma B16F10 cells
kept in vitro, which indicates that the receptor is
expressed by cells from the tumour microenvironment
rather than the tumour cells themselves.
Clearance of dead cells by professional phagocytes
such as macrophages may lead to the secretion of cyto-
kines that favour tumour growth [27]. The endogenous
lectin galectin-3 is among the activation markers of
macrophage/dendritic cells, playing a role as an opsonin
[28] and as a modulator of cell migration [29]. Macro-
phages expressing galectin-3 are driven towards the
alternative pathway of activation [30], usually associated
with the M2 phenotype, which favours tumour growth
and angiogenesis [31]. Here we showed a significant
reduction in the proportion of galectin-3-expressing
infiltrating macrophages/dendritic cells within the
tumour microenvironment of WEB2170-treated mice
but not in the spleen white pulp of animals treated with
both DTIC and/or WEB2170. Together, these results
suggest that engagement of PAF-R interferes with
selected pathways in macrophages, changing their phe-
notype into that of a suppressor. This suggestion is rein-
forced by the slight but significant decrease in
microvascular density observed in WEB2170-treated ani-
mals. Indeed, the activation of macrophage PAF-R plays
a role in macrophage-derived angiogenesis [31]. As
macrophages/dendritic cells are central actors in the
maintenance of both normal and tumour tissue homeos-
tasis, novel pharmacological interventions that may con-
trol their functions are warranted. For cancer therapy,
inhibitors of PAF-R-dependent pathways are promising
candidates for adjuvant therapy, as they can act in both
tumour cells and host cells, e.g., by attenuating the pro-
tumoural activities of suppressor macrophages.
Conclusions
The data suggest that PAF-R-dependent pathways are
activated during experimental tumour growth, modifying
the phenotype of tumour macrophages and the micro-
environment in such a way as to favour tumour growth.
Combination therapy with a PAF-R antagonist and a
chemotherapeutic drug may represent a new and pro-
mising strategy for the treatment of some tumours.
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